Suppression of oncogenic viral interferon regulatory factor (vIRF) of Kaposi's sarcoma-associated herpesvirus by ribozyme-mediated cleavage

Cancer Gene Therapy

Volumn 8, Issue 4, 2001, Pages 285-293

  Zhang, Yan Jin ^a   Wang, Xin Ping ^a   Deng, Jian Hong ^a   Salinas, Richard A ^b   Oishi, Noboru ^b   Gao, Shou Jiang ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b University of Texas Health Science Center at San Antonio   (United States)

Author keywords

Kaposi's sarcoma associated herpesvirus; KSHV; Oncogene; Ribozyme; vIRF

Indexed keywords

INTERFERON REGULATORY FACTOR 1; RIBOZYME;

ANTIBODY SPECIFICITY; ARTICLE; DRUG EFFECT; FLOW CYTOMETRY; GENE THERAPY; GROWTH REGULATION; HUMAN; HUMAN CELL; KAPOSI SARCOMA; ONCOGENE; PRIORITY JOURNAL; PROTEIN FAMILY; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; TUMOR GROWTH; VIRUS GENE;

ANIMALS; BASE SEQUENCE; DNA-BINDING PROTEINS; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HELA CELLS; HERPESVIRUS 8, HUMAN; HUMANS; INTERFERON REGULATORY FACTORS; MICE; MOLECULAR SEQUENCE DATA; OPEN READING FRAMES; RNA, CATALYTIC; RNA, MESSENGER; TRANSCRIPTION FACTORS; TRANSFECTION; VIRAL PROTEINS;

HERPESVIRIDAE; HERPESVIRUS 8; HUMAN HERPESVIRUS 8;

EID: 0034997682     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700299     Document Type: Article

References (31)

1. Schulz TF. Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8). J Gen Virol. 1998;79:1573-1591.
2. Gao SJ, Boshoff C, Jayachandra S, et al. KSHV ORF K9 (vIRF) is an oncogene which inhibits the interferon signaling pathway. Oncogene. 1997;15:1979-1985.
3. Zimring JC, Goodbourn S, Offermann MK. Human herpesvirus 8 encodes an interferon regulatory factor (IRF) homolog that represses IRF-1-mediated transcription. J Virol. 1998;72: 701-707.
4. Li M, Lee H, Guo J, et al. Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor. J Virol. 1998;72: 5433-5440.
5. Burysek L, Yeow WS, Lubyova B, et al. Functional analysis of human herpesvirus 8-encoded viral interferon regulatory factor 1 and its association with cellular interferon regulatory factors and p300. J Virol. 1999;73: 7334-7342.
6. Jayachandra S, Low KG, Thlick AE, et al. Three unrelated viral transforming proteins (vIRF, EBNA2, and E1A) induce the MYC oncogene through the interferon-responsive PRF element by using different transcription co-adaptors. Proc Natl Acad Sci USA. 1999;96:11566-11571.
7. Mamane Y, Heylbroeck C, Genin P, et al. Interferon regulatory factors: the next generation. Gene. 1999;237:1-14.
8. WAF1/CIP1 mediated by STAT1. Science. 1996;272:719-722.
9. Dimri GP, Nakanishi M, Desprez PY, et al. Inhibition of E2F activity by the cyclin-dependent protein kinase inhibitor p21 in cells expressing or lacking a functional retinoblastoma protein. Mol Cell Biol. 1996;16:2987-2997.
10. Tanaka N, Ishihara M, Taniguchi T. Suppression of c-myc or fos B-induced cell transformation by the transcription factor IRF-1. Cancer Lett. 1994;83:191-196.
11. Jonak GJ, Knight E Jr. Selective reduction of c-myc mRNA in Daudi cells by human beta interferon. Proc Natl Acad Sci USA. 1984;81:1747-1750.
12. James HA, Gibson I. The therapeutic potential of ribozymes. Blood. 1998;91:371-382.
13. + hematopoietic progenitor cells transduced with an anti-HIV ribozyme. Hum Gene Ther. 1999;10:2255-2270.
14. Wong-Staal F, Poeschla EM, Looney DJ. A controlled, Phase 1 clinical trial to evaluate the safety and effects in HIV-1-infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA. Hum Gene Ther. 1998;9:2407-2425.
15. Funato T, Yoshida E, Jiao L, et al. The utility of an anti-fos ribozyme in reversing cisplatin resistance in human carcinomas. Adv Enzyme Regul. 1992;32:195-209.
16. Scanlon KJ, Jiao L, Funato T, et al. Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein. Proc Natl Acad Sci USA. 1991;88:10591-10595.
17. Kashani-Sabet M, Funato T, Tone T, et al. Reversal of the malignant phenotype by an anti-ras ribozyme. Antisense Res Dev. 1992;2:3-15.
18. Funato T, Shitara T, Tone T, et al. Suppression of H-ras-mediated transformation in NIH3T3 cells by a ras ribozyme. Biochem Pharmacol. 1994;48:1471-1475.
19. Hua J, Muschel RJ. Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res. 1996;56:5279-5284.
20. Sehgal G, Hua J, Bernhard EJ, et al. Requirement for matrix metalloproteinase-9 (gelatinase B) expression in metastasis by murine prostate carcinoma. Am J Pathol. 1998;152:591-596.
21. Haseloff J, Gerlach WL. Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature. 1988;334: 585-591.
22. Mathews DH, Sabina J, Zuker M, et al. Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure. J Mol Biol. 1999;288:911-940.
23. Cesarman E, Moore PS, Rao PH, et al. In vitro establishment and characterization of two acquired immunodeficiency syndrome-related lymphoma cell lines (BC-1 and BC-2) containing Kaposi's sarcoma-associated herpesvirus-like (KSHV) DNA sequences. Blood. 1995;86:2708-2714.
24. Chen S, Song CS, Lavrovsky Y, et al. Catalytic cleavage of the androgen receptor messenger RNA and functional inhibition of androgen receptor activity by a hammerhead ribozyme. Mol Endocrinol. 1998;12:1558-1566.
25. Halatsch ME, Schmidt U, Botefur IC, et al. Marked inhibition of glioblastoma target cell tumorigenicity in vitro by retro-virus-mediated transfer of a hairpin ribozyme against deletion-mutant epidermal growth factor receptor messenger RNA. J Neurosurg. 2000;92:297-305.
26. Abounader R, Ranganathan S, Lal B, et al. Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression. J Natl Cancer Inst. 1999;91:1548-1556.
27. Tsuchida T, Kijima H, Oshika Y, et al. Hammerhead ribozyme specifically inhibits mutant K-ras mRNA of human pancreatic cancer cells. Biochem Biophys Res Commun. 1998;253:368-373.
28. Lo KM, Biasolo MA, Dehni G, et al. Inhibition of replication of HIV-1 by retroviral vectors expressing tat-antisense and anti-tat ribozyme RNA. Virology. 1992;190:176-183.
29. Irie A, Anderegg B, Kashani-Sabet M, et al. Therapeutic efficacy of an adenovirus-mediated anti-H-ras ribozyme in experimental bladder cancer. Antisense Nucleic Acid Drug Dev. 1999;9:341-349.
30. Yamazaki H, Kijima H, Ohnishi Y, et al. Inhibition of tumor growth by ribozyme-mediated suppression of aberrant epidermal growth factor receptor gene expression. J Natl Cancer Inst. 1998;90:581-587.
31. Seo T, Lee D, Lee B, et al. Viral interferon regulatory factor 1 of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) binds to, and inhibits transactivation of, CREB-binding protein. Biochem Biophys Res Commun. 2000;270: 23-27.